Education
About Us
Working with TipRanks
Follow Us
Novo Nordisk (NVO)
:NVO
NVO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$45.05 - $139.74
Previous CloseN/A
Volume3.65M
Average Volume (3M)18.86M
Market Cap
$222.63B
Enterprise Value$319.55B
Total Cash (Recent Filing)$41.55B
Total Debt (Recent Filing)$118.72B
Price to Earnings (P/E)13.7
Beta1.04
Next Earnings
Nov 05, 2025EPS Estimate
0.95Next Dividend Ex-Date
Aug 18, 2025Dividend Yield3.24%
Share Statistics
EPS (TTM)0.93
Shares Outstanding3,390,128,000
10 Day Avg. Volume42,172,587
30 Day Avg. Volume18,862,160
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.44
Enterprise Value/Revenue1.05
Enterprise Value/Gross Profit1.25
Enterprise Value/Ebitda2.07
Forecast
1Y Price Target
$65.83Price Target Upside32.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Leadership ChangeA new CEO, Mike Doustdar, has been appointed, potentially bringing a global perspective and re-energizing the struggling strategy.
Pipeline InnovationNovo Nordisk is committed to driving the next wave of pipeline innovation.
Product DevelopmentNovo Nordisk is pushing ahead with high-dose oral semaglutide for the treatment of obesity as an option for patients who may not want to use injectables.
Bears Say
Competitive PressureOzempic's US underperformance is accentuated by competition in the US, leading to weaker-than-expected sales.
Market CompetitivenessNovo Nordisk shares are expected to remain less competitive versus other peers in the cardiometabolic market.
Sales PerformanceLower Wegovy sales expectations were specifically impacted by continued/higher-than-expected compounding in the US market and slower-than-expected market expansion.
Novo Nordisk News
NVO FAQ
What was Novo Nordisk’s price range in the past 12 months?
Novo Nordisk lowest stock price was $45.05 and its highest was $139.74 in the past 12 months.
What is Novo Nordisk’s market cap?
Novo Nordisk’s market cap is $222.63B.
When is Novo Nordisk’s upcoming earnings report date?
Novo Nordisk’s upcoming earnings report date is Nov 05, 2025 which is in 84 days.
How were Novo Nordisk’s earnings last quarter?
Novo Nordisk released its earnings results on Aug 06, 2025. The company reported $0.929 earnings per share for the quarter, beating the consensus estimate of $0.921 by $0.008.
Is Novo Nordisk overvalued?
According to Wall Street analysts Novo Nordisk’s price is currently Undervalued.
Does Novo Nordisk pay dividends?
Novo Nordisk pays a Semiannually dividend of $0.412 which represents an annual dividend yield of 3.24%. See more information on Novo Nordisk dividends here
What is Novo Nordisk’s EPS estimate?
Novo Nordisk’s EPS estimate is 0.95.
How many shares outstanding does Novo Nordisk have?
Novo Nordisk has 3,390,128,000 shares outstanding.
What happened to Novo Nordisk’s price movement after its last earnings report?
Novo Nordisk reported an EPS of $0.929 in its last earnings report, beating expectations of $0.921. Following the earnings report the stock price went down -3.897%.
Which hedge fund is a major shareholder of Novo Nordisk?
Currently, no hedge funds are holding shares in NVO
Novo Nordisk Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$65.83 (32.24% Upside)
$65.83 (32.24% Upside)
Blogger Sentiment
Bullish
NVO Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 617.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.2%
Last 30 Days ▲ 12.3%
Last 30 Days ▲ 12.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.13%
12-Months-Change
Fundamentals
Return on Equity
75.95%
Trailing 12-Months
Asset Growth
42.90%
Trailing 12-Months
Company Description
Novo Nordisk
Novo Nordisk is a global healthcare company headquartered in Denmark, specializing in the development and manufacturing of pharmaceuticals for diabetes care, obesity management, and other chronic diseases. Established in 1923, the company operates primarily in the biopharmaceutical sector, focusing on insulin and GLP-1 receptor agonists for diabetes treatment, as well as hormone replacement therapy and treatments for hemophilia and growth disorders. Novo Nordisk is recognized for its commitment to innovation and sustainability within the healthcare industry.
NVO Company Deck
NVO Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture of significant growth in overall sales and strategic advancements in R&D and capacity expansion, countered by a lowered full-year outlook and challenges in the U.S. and China markets. The positive sales and profit growth are overshadowed by the lowered expectations and ongoing challenges in the market.View all NVO earnings summariesNVO Stock 12 Month Forecast
Average Price Target
$65.83
▲(32.24% Upside)
Technical Analysis
Ownership Overview
―
Insiders
1.40% Mutual Funds
0.38% Other Institutional Investors
98.13% Public Companies and Individual Investors